The methods being presented demonstrate laboratory procedures for the isolation of organs from Zika virus infected animals and the quantification of viral load. The purpose of the procedure is to quantify viral titers in peripheral and CNS areas of the mouse at different time points post infection or under different experimental conditions to identify virologic and immunological factors that regulate Zika virus infection. The organ isolation procedures demonstrated allow for both focus forming assay quantification and quantitative PCR assessment of viral titers. The rapid organ isolation techniques are designed for the preservation of virus titer. Viral titer quantification by focus forming assay allows for the rapid throughput assessment of Zika virus. The benefit of the focus forming assay is the assessment of infectious virus, the limitation of this assay is the potential for organ toxicity reducing the limit of detection. Viral titer assessment is combined with quantitative PCR, and using a recombinant RNA copy control viral genome copy number within the organ is assessed with low limit of detection. Overall these techniques provide an accurate rapid high throughput method for the analysis of Zika viral titers in the periphery and CNS of Zika virus infected animals and can be applied to the assessment of viral titers in the organs of animals infected with most pathogens, including Dengue virus.
Introduction
Zika virus (ZIKV) is an arbovirus that belongs to the flaviviridae family, which includes important neuroinvasive human pathogens such as Powassan virus (POWV), Japanese encephalitis virus (JEV), and West Nile virus (WNV) 1 . Following its isolation and identification, there have been periodic reports of human ZIKV infections in Africa and Asia 2, 3, 4, 5 , and epidemics within Central and South America (reviewed in reference 6 ). However, it was not until recently that ZIKV was thought to cause severe disease 7 . Now there are thousands of cases of neurological disease and birth defects linked to ZIKV infections. The rapid emergence of ZIKV has prompted many questions relating to: why there is an increase in disease severity, what is the immunological response to ZIKV infection and are there viral and/or immune mediated pathologies linked to the increase in neurological manifestations and birth defects. There is now a rush to understand the central nervous system (CNS) related disease associated with ZIKV as well as the need to rapidly test the efficacy of the antivirals and vaccines against ZIKV. It is against this backdrop that we have developed methods for the rapid analysis of ZIKV titers in both the periphery and CNS using a ZIKV-specific focus forming assays (FFA).
Small animal models are important for understanding disease progression and for the early evaluation of vaccines, therapeutics, and antivirals. We have established small animal models for the study of arbovirus disease by using various mouse strains to model human infection and protection against viral pathogens 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 . Using this prior experience, we began to modify techniques used for the assessment of WNV and Dengue virus, a related flavivirus for the assessment of ZIKV titer in both peripheral organs as well as the CNS 21, 23, 24 .
The advantages of these methods over other assays are: 1) that they combine the ability to harvest both peripheral and CNS organs for the analysis; 2) the methods are adaptable for flow cytometry, for measurements of innate and adaptive immune responses, along with viral titers on the same animal in the same organ; 3) the harvest technique is adaptable for histological analysis; 4) the ZIKV FFA is a rapid high throughput method for viral titer analysis; and 5) these methods can be applied to the assessment of viral titers in the organs of animals infected with most pathogens 1. Organ Isolation NOTE: The virus is not stable at room temperature (RT) so the number of animals harvested at one time must be planned carefully to preserve viral titers. 7. Fill the 20 mL syringe with PBS, at room temperature (or 37 °C), and perfuse mice by inserting the butterfly needle into the left ventricle. Puncture the right atrium to allow blood and PBS to exit. Slowly administer the PBS while checking the color of the liver to confirm that the animal is completely perfused. Liver should change from deep red to pink salmon color.
1. If preparing the organs for histology, leave butterfly needle in place and then perfuse with 20 mL of ice cold 4% paraformaldehyde. If so, it is convenient to have the syringe connected to a 3-way stopcock with both syringes attached to it, turning the valve ON and OFF as one alternates between PBS and PFA.
8. Harvest organs into labeled, weighed tubes. For peripheral organs, follow an established order for harvest: liver, spleen, kidney and lungs.
1. Take only one lobe from the liver; it does not matter which one, but for all experiments always try to take the same lobe with the same size piece. Similarly, for kidneys and lungs, take the same kidney and lung. If flow cytometry is also to be completed, any organ can be cut in half. Store the half to be used for cytometry in Roswell Park Memorial Institute medium (RPMI) at room temperature until the harvest is complete. 2. Immediately after harvest, put each organ in a labeled tube and place in the dry ice bath. Virus titer reduces over time at room temperature, so the amount of time it takes to harvest organs is extremely important. There must be consistency between mice, so after safety, the next priority is speed. NOTE: If harvesting organs for viral titers, it is very helpful to have a second individual harvest the brain at this point, to preserve viral titers.
9. Remove the remaining organs from the mouse body cavity to gain access to the spine and skull. 1. Remove the mouse from the board and remove the pelt, followed by the removal of the arms and legs. Remove the head of the mouse with a decapitation, blunt or surgical scissors to harvest the brain by cutting the skull with a serrated LaGrange scissors through the foramen magnum. Then, peel off the skull with forceps and scoop out the brain with a spatula. 2. Using strong, blunted scissors, remove the ribs and other bones surrounding the spine. Then, cut across the pelvic bone, exposing the vertebral foramen at the lumbar level. The small tip of the spinal cord should be visible at this point. 3. Use a 10 mL syringe filled with PBS and a 18 G needle to expel the spinal cord by "flushing" the cord from lumbar to cervical spine over a Petri dish.
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10. Repeat the procedure with all the animals until the harvest is completed. Place the harvest tools in the 70% ethanol between animals. Focus on consistency and speed. The length of time between each organ harvest should remain consistent so as to not bias viral titer results. 11. When finished, disinfect the biosafety cabinet and all material prior to removing it from the animal facility. 12. Remove each tube from the ice bath and weigh tubes to determine organs weight. To determine the organs weight, subtract the weight of the empty tube from the weight of the organ containing tube. NOTE: At this point organs can be frozen at -80 °C to further process at a later date or organs can be homogenized immediately before freezing individual aliquots. Freeze thawing samples multiple times decreases viral titer. Therefore, it is important to do same procedure for all experiments within a single project.
Organ Homogenization
1. Prepare 3 labeled, 1.5 mL snap-capped tubes for each organ to be homogenized.
2. If samples are not being homogenized immediately after harvest, remove tubes from -80 °C. The samples do not need to be thawed to homogenize. 3. Put the samples on ice to keep them cold to minimize viral titer loss. Then, add 1 mL of cold DMEM containing 5% FBS to each organ containing tube. 4. Immediately beat tubes in bead beater according to manufacturer's instructions. Homogenize all organs with steel beads in a beadhomogenizer instrument. Check to ensure each organ has been completely homogenized. 5. Spin down organ debris in microfuge at 12,000 x g for 5 min in a microfuge that has been chilled to 8 °C. Then return the tubes to the ice bucket. In the biosafety cabinet, aliquot samples into tubes for necessary assays. Then return the tubes to the ice bucket. 6. For focus forming assay, aliquot 500 µL into a labeled tube. Then place tubes in the rack on an ice bucket. Aliquot 50 µL into a tube for RNA for fluorogenic quantitative RT-PCR (qRT-PCR) to measure viral genome copy number. 7. Isolate total RNA from the organs of the infected animals using a commercial RNA isolation kit. Determine flavivirus viral RNA using the primer probe sets specific for ZIKV, which recognizes unique sequences in each flavivirus genome. Determine viral copy number using a copy control plasmid containing a defined positive single-stranded RNA generated in vitro using T7 polymerase containing the ZIKV target sequences. 8. Aliquot the remaining sample, which is approximately 300 µL, into the third tube and store at -80 °C if needed.
NOTE: If samples were not previously frozen, freeze at -80 °C. If samples had been previously frozen, continue onto the focus forming assay and/or RNA isolation before stopping.
Zika Virus Focus Forming Assay

NOTE:
It is important to include a no virus control and a positive control. The positive control is a dilution series of a virus stock with a known concentration. Not all controls need to be on the same plate, but as the assay becomes larger than 5 plates, more controls should be added, and spread out among plates. Take care not to scratch the monolayer with either the pipet tips or by vigorous washing. Multiple organs can be titered on the same day or on different days. But an individual organ should not be titered over multiple days because different assay conditions can impact viral titer. It is strongly recommended to run an individual organ on a single day.
1. Prior to the day of the assay, prepare the cells and reagents needed for the focus forming assay. 1. Prepare growth media containing 500 mL of DMEM with 5 mL of HEPES and 25 mL of FBS. Have Vero-World Health Organization (WHO) cells growing in growth media at 37 °C, 5% CO 2 prior to the start of the assay. The Vero cells should not be a high passage or ever grown over 100% confluency prior to the start of the assay. 2. Prepare 500 mL of a 2% methylcellulose solution by autoclaving a 1 L glass media bottle with 10 g of methylcellulose and a large stir bar and a separate 1 L glass media bottle with 500 mL of H 2 O. If the autoclaved water has cooled reheat in microwave until bottle is hot to the touch, but not boiling. 3. Gently pour warm/hot water into bottle of methylcellulose while in the tissue culture hood. Partially cap bottle and stir on the hotplate until methylcellulose is in solution (1-4 h). Aliquot the 2% methylcellulose solution into sterile 50 mL conical tube. 2% Methylcellulose can be stored at 4 °C until needed. 4. Prepare a 5% Paraformaldehyde solution in PBS for fixing the plates and stored at 4 °C until needed. Prepare a 1x focus forming assay wash buffer by adding 0.05% Triton X-100 to PBS and stored at RT. Prepare a 1x FFA staining buffer by adding 1 mg/mL saponin to PBS and stored at 4 °C until needed. These can be prepared one-two weeks in advance. 
Representative Results
To evaluate ZIKV titers using the protocol described above Ifnar1 -/mice were infected with ZIKV (PRVABC59) via subcutaneous (SC) injection to the footpad. Here, the administration of 1 x 10 5 FFU of ZIKV to 8-12 week old Ifnar1 -/mice SC is not lethal but the virus can replicate in both the periphery and CNS. This dose and route are used to study host pathogen immune responses and pathogenicity. Administration of 1 x 10 5 FFU of ZIKV to a 8-12 week old Ifnar1 -/mouse intravenous (IV) injection is between 80 to 100% lethal, with the animal succumbing to infection between 8 to 14 days post virus injection. We routinely use this administration route to determine efficacy of antivirals and therapeutics, as well as preclinical vaccine candidate testing.
Four 10-12 week-old Ifnar1 -/mice were infected with 1 x 10 5 FFU of ZIKV SC and spleens, livers, kidneys, spinal cords and brains were harvested four days post infection by the methods detailed above (Figure 1) . The amount of ZIKV in the tissues was assayed by focus forming assay (FFA) using Vero cells in a 96 well format as described above. Using the FFA, tissue viral load is expressed as focus forming units (FFU) per g of tissue. Similar to what was observed in a previous study of ZIKV infection of Ifnar1 -/-26 , we saw viremia following a sampling of viral titers in different organs four days post ZIKV infection. These results indicate that the methods used for organ harvest and tittering by focus forming assay can be used to detect titer in both peripheral organs and the CNS within the same animal. Interestingly, we did not expect to see high viral titers in both the periphery and the CNS four days post infection in the Ifnar1 When performing the focus forming assay (FFA), there are multiple technical mistakes an investigator can make which will result in suboptimal FFA results. The most common mistakes are: 1) organ toxicity; 2) vigorous pipetting; 3) fiber contamination; and 4) incorrect cell plating density. We discuss each of these issues below and illustrate the outcome in Figure 2 . One of the more common issues that occurs with both the FFA and plaque assay is organ toxicity (Figure 2A red arrow) . We believe organ toxicity is driven by the high concentration of intracellular components released during organ homogenization. Organ toxicity varies based upon the organ and is seen in organs harvested from uninfected animals, with the liver being the most toxic and the spleen the least. Toxicity is reduced as the organ is serially diluted on the FFA plate. However, toxicity alters the sensitivity of the assay resulting in a change in the limit of detection. As shown in Figure 2A if the viral titer in the organ is lower than the toxicity the FFA will not be able to accurately record the viral titers. Figure 2B illustrates toxicity in wells a1-4, but the viral titer is sufficiently high to overcome organ toxicity as seen in wells b3 and b4. To overcome this limitation in the FFA, we also perform quantitative real-time PCR on organ titer samples. In Figure 2C , we illustrate several common technical errors. Vigorous pipetting or washing can remove the monolayer (Figure 2C, *) , if this occurs in wells with foci that data will be lost leading to inaccurate reporting of titer results. Fibers or hairs, that are present in lab bench absorbent paper can contaminate individual wells (Figure 2C, $) this can cause significant errors if using an automated counting program. While most automated counting programs have fiber exclusion options, we have not found it to be highly effective at excluding fibers from the analysis. The solution to this is to manually count the wells, which can be very time consuming and is not practical for the analysis of large assays. Cell density is another issue which can dramatically impact the success of a focus forming assay ( Figure 2D ). If cells are not at the right density at the start of the assay the number and size of the spots will be impacted. As shown in Figure 2D , columns 1-3, cells at approximately 60% confluency at the start of the assay compared to cells plated at 90% confluency columns 4-6 will dramatically impact the focus forming assay. To overcome this obstacle small pilot assays should be run to optimize cell density and fixation times as individual laboratory conditions will impact the success for the assay.
For studies when different groups of infected animals are compared, the statistical analysis that is performed is dependent on the distribution of data. Either, parametric or nonparametric tests are used to assess statistical significance. For parametric tests, ANOVA is utilized to detect overall effect, and individual treatment groups will be compared using Dunn's test. In case the distribution of data does not satisfy requirements for parametric analysis, nonparametric tests are employed. The Kruskal-Wallis test is used to detect the overall treatment effect, and the Mann-Whitney U test is used to perform pair-wise comparisons. For the results present here we did not compare the animals with a second data set harvested at this time point so we did not perform statistical analysis on the data set shown. 
Discussion
ZIKV infection can cause a neurological disease therefore the current animal models to study pathogenesis, immune responses and protective efficacy of vaccines and antivirals need to focus on viral control within the CNS. One of the challenges in focusing on CNS disease is that it often comes at the expense of studying peripheral infection. The organ isolation methods proposed here focuses on the need to rapidly evaluate ZIKV infection in both the periphery and the CNS in order to assess CNS mediated ZIKV associated disease and establish a model for preclinical testing of antivirals, therapeutic and vaccines. An added benefit of this technique is that it also allows for a high degree of flexibility, including the combined study of immunological responses to ZIKV or histological analysis of infection. This technique, is not restricted to just ZIKV but can also be universally applied to study a range of host-pathogen interactions, including flaviviruses such as Dengue virus 21 , orthopoxviruses like monkeypox and ectromelia. The considerations and drawbacks to this technique of harvesting focus mainly of the capabilities of the experimenter. As ZIKV is not stable for long periods of time at room temperature, the amount of time it takes to harvest organs after perfusion can significantly impact the quality of the results. For most experiments that we have performed, we compare viral titers from mice treated with two conditions, so we focus our efforts on consistency of time between organ harvests not on speed. In this way the same person performs the same procedure for the whole experiment to maintain consistency. The other major consideration with this procedure is safety, we have readily performed these methods with BSL-2 (ZIKV, Dengue virus) and BSL-3 (WNV, Chikungunya virus) pathogens. It is very important to perform all procedures in a clean, well maintained, certified biosafety cabinet with disinfectant.
An FFA parallels the plaque assay, except that it uses peroxidase immunostaining to identify foci of infected cells, rather than plaques. My laboratory as well as multiple other laboratories have now successfully switched to using FFAs for all our tittering experiments 11, 14, 15, 17, 26, 27, 28 . The FFA has multiple advantages over the traditional plaque assay: a) The FFA is faster, requiring a shorter incubation compared to a plaque assay, b) it is also higher-throughput, being performed in 96-well plates. The 96 well plate format can also accommodate smaller volumes of starting material. In addition, c) the FFA is compatible with the use of an automated plate washer and automated spot counter, greatly reducing the labor and time required for the assay. The FFA has more steps after infection, but d) with the use of multichannel pipets, or even a pipetting robot, the timing for most of the assay steps after fixation are flexible and the assay can be paused overnight or for longer. Finally, e) it may be especially useful for virus strains that do not form clear plaques, such as Dengue virus. One disadvantage of the FFA is that it requires specific antibodies to detect virus-infected cells, which may be confounding when considering diverse virus strains or mutant viruses. For the FFA as with the plaque assay the density of the cell monolayer at the time of infection is critical for the success of the assay. Cells should be used at
